Precise Genome Editing for Plant Engineering with GeneArt® Precision TALs
Life Technologies’ TAL Effector Proteins Called a “Game Changer” in Agriculture
CARLSBAD, Calif. – October 9, 2011 – -- Life Technologies Corporation recently launched the GeneArt® Precision TALs, generally referred to as TAL effector proteins (TALE), which allow plant researchers the ability to edit genomes and control gene activity with unprecedented precision and reliability.
The TAL effectors have broad utility in plant sciences, from biofuel feed stocks to agricultural crop plant engineering to basic plant biology research.
“We’re very excited about this technology and its implications for plant science research,” said Nathan Wood, vice president of synthetic biology at Life Technologies. “With GeneArt® Precision TAL technology, scientists are provided research use access with a clear licensing path for commercial use through the Two Blades Foundation, making it the first technology of its kind ideal for plant and ag bio researchers.”
TAL effectors can be designed to bind to specific DNA sequences selected by researchers and can deliver a variety of functional elements to activate or repress gene expression or to cut and insert DNA with precision. TAL proteins have an advantage over competing zinc finger technology in that they are simpler to design, bind with greater specificity, displaying fewer “off-target” events.
“People realize now that transgenes should be precisely expressed in plant tissues and at certain times—just as nature does it,” said Neal Stewart, Ph.D., professor of plant sciences at the University of Tennessee, Knoxville. “Synthetic biology offers the prospects of designing promoters to tightly regulate gene expression.”
TALs have the unique capabilities of being targeted, robustly, to promoters in plants—both endogenous promoters and our engineered synthetic promoters—to boost gene expression in a predictable way. The simple TAL effector translation code allows researchers to specifically design TAL binding proteins to bind to a DNA sequence of choice. Researchers specify a sequence they wish to target, and receive a gene encoding the TAL protein that will target it.
“Synthetic biology is just showing up in agricultural and environmental plant research,” said Stewart. “We are making quantum leaps at being able to have an order of precision in gene expression that was unavailable just a few years ago.
“Couple precision with metabolic engineering, and there you have a game-changer in agriculture.”
GeneArt® Precision TALs are supplied as Gateway® compatible entry clones encoding a DNA binding protein for a specific customer-submitted sequence fused to a range of customer selected effector domains. Custom TALs will typically be delivered within two weeks after orders are placed.
The Two Blades Foundation is a U.S.-based charitable organization that is committed to making the technology broadly available.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today’s most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com.
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies’ anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact: